The invention features chlorite in an amount effective to decrease blood immune cell activation for use in treating a macrophage-associated neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), or multiple sclerosis (MS) in a subject. The invention also describes means for monitoring therapy by assessing blood immune cell activation before and after therapy.